Clinical trial
Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational…
NCT02625961 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT02625961 |
|---|---|
| Title | Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057) |
| Official title | A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) and Pembrolizumab in Combination With Other Investigational Agents in Subjects With High Risk Non-muscle-Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Bladder Cancer |
| Intervention type | Biological |
| Interventions | Pembrolizumab, Pembrolizumab/vibostolimab coformulation, Favezelimab/pembrolizumab coformulation |
| Enrollment | 296 |
| Start date | Feb 10, 2016 |
| Primary completion | Nov 5, 2025 |
| Completion | Nov 5, 2025 |
| First posted | Dec 9, 2015 |
| Last update posted | Nov 21, 2025 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: